ClinicalTrials.gg
CompletedNCT00103571Updated Nov 6, 2007

Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

A Phase 4 interventional study of Olanzapine and Aripiprazole in Schizophrenia, sponsored by Eli Lilly and Company. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2007-11-06.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
9th of 94
600 · median 114
Started
2004
with 9 others
Phase 4
46 of 97
1 open now
Registered
16th of 97
by date
Lead sponsor
22 of 97
Eli Lilly and Company

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 9th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2004, is one of 46 in phase 4, and was the 16th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have schizophrenia, schizoaffective disorder, or schizophreniform disorder
  • Patients must be agitated
  • Patients must display psychotic symptoms
  • Patients must be inpatients who are expected to stay in the hospital for at least 5 days
  • Patients must be 18 to 55 years of age

Exclusion criteria

Exclusion Criteria:

  • Patients may not be hospitalized for greater than 72 hours prior to study start
  • Patients may not have received more than one dose of olanzapine or aripiprazole within 72 hours prior to study start
  • Patients may not be actively suicidal
  • Patients may not be diagnosed with substance-induced psychosis or substance dependence
  • Patients may not have acute, serious, or unstable medical conditions
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
600 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to test the hypothesis that olanzapine is superior to aripiprazole in the reduction of symptoms of agitation in acutely ill patients with schizophrenia, as measured by mean change in the

  2. Positive and Negative Syndrome Scale Excited Component (PANSS-EC) over 5 days of treatment (4 continuous 24 hr treatment exposures). The null hypothesis of the study is that there is no difference between olanzapine and

  3. aripiprazole in reducing agitation.

Secondary outcomes

  1. The reduction in positive symptoms as measured by the Brief Psychiatric Rating Scale Positive subscale (PBRS Positive);

  2. The reduction of symptoms of agitation as measured by Overt Agitation Severity Scale (OASS);

  3. The proportion of patients responding to treatment and the time to response based on varying levels in the percent reduction of

  4. the PANSS_EC from baseline;

  5. The reduction in overall severity of psychiatric illness as measured by the Clinical Global Impression-Severity Scale (CGI-S);

  6. The intensity of nursing intervention (e.g. seclusion, restraint, special nursing watch), as measured by the Global Assessment

  7. of Nursing Intervention

  8. The proportion of patients using pm lorazepam and the time-course of usage.

  9. The proportion of patients discontinuing from the study due to lack of efficacy or due to adverse events related to worsening

  10. of psychiatric illness.

  11. Patient satisfaction with their medication, as measured by Drug Attitude Inventory (DA1-10).

  12. A sensitivity analysis will be performed on two randomly chosen subsamples of the overall patient population by analyzing the

  13. primary objective respectively.

  14. Additional secondary objectives of the study are to compare the safety of olanzapine versus aripiprazole over the course of 5

  15. days in the treatment of acutely ill patients with schizophrenia as assessed by:

  16. Relative degree of sedation as measured by the Agitation Calmness Evalution Scale (ACES);

  17. Review of spontaneous (unsolicited) treatment emergent adverse events;

  18. Development of extrapyramidal symptoms as assessed by daily Modified Simpson-Angus and Barnes Akathisia scale scores.

07

Study locations

5 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
    St Charles, Missouri 63301, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
    Beachwood, Ohio 44122, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
    Canton, Ohio 44708, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
    Memphis, Tennessee 38117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
    Rio Piedras, 00926, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2005
First posted
Feb 11, 2005
Start
Jul 2004
CompletionActual
Aug 2006
Last update
Nov 6, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00103571
First posted
Feb 11, 2005
Start date
Jul 2004
Completion
Aug 2006
Last update
Nov 6, 2007

Study contacts

Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olanzapine · Aripiprazole

Start the discussion